Design Therapeutics will present Phase 1/2 trial data for DT-216P2 in Friedreich's ataxia on May 18, 2026.
Quiver AI Summary
Design Therapeutics, Inc. will announce results from its Phase 1/2 RESTORE-FA trial testing the drug DT-216P2 for Friedreich’s ataxia on May 18, 2026. The company, based in Carlsbad, California, focuses on developing treatments for serious genetic diseases using its GeneTAC® technology, which targets disease-causing genes. A conference call and webcast will take place at 8:00 a.m. ET, and the presentation will be accessible on the company's website for 30 days afterward. In addition to DT-216P2, Design Therapeutics is also working on therapies for other conditions, including Fuchs endothelial corneal dystrophy and myotonic dystrophy type-1, and has ongoing discovery efforts related to Huntington’s disease and other genomic medicines.
Potential Positives
- Design Therapeutics will announce data from the Phase 1/2 RESTORE-FA trial, which is a significant step in the development of their treatment for Friedreich’s ataxia, showcasing progress in their clinical pipeline.
- The live conference call and webcast provide transparency and direct communication with investors, indicating the company's commitment to keeping stakeholders informed about their advancements.
- The mention of a diverse pipeline with multiple drug candidates for serious genetic diseases, including Huntington’s disease, highlights the company's innovative approach and potential to address various unmet medical needs.
- Design Therapeutics utilizes its GeneTAC® platform, a novel technology that targets disease-causing genes, which positions the company at the forefront of cutting-edge genetic therapies.
Potential Negatives
- The announcement of the conference call and data presentation may indicate that the company is under pressure to provide updates on its clinical trials, which could suggest uncertainty about their progress or results.
- The focus on multiple clinical trials may dilute investor confidence, as stakeholders might worry about resource allocation and the ability to effectively manage multiple developments simultaneously.
- There is no indication in the press release of positive outcomes or supportive data from the ongoing trials, which could lead to speculation about the efficacy of their treatments.
FAQ
What is the RESTORE-FA trial about?
The RESTORE-FA trial evaluates the efficacy of DT-216P2 in patients with Friedreich’s ataxia, a serious genetic disease.
When will Design Therapeutics announce the trial results?
Design Therapeutics will announce data from the ongoing Phase 1/2 RESTORE-FA trial on May 18, 2026.
How can I access the live webcast of the announcement?
The live webcast can be accessed on Design Therapeutics' website at www.designtx.com.
What is GeneTAC® technology?
GeneTAC® technology involves gene-targeted chimera small molecules designed to modulate disease-causing gene expressions.
What other programs are under development at Design Therapeutics?
In addition to DT-216P2, the company is developing DT-168 for Fuchs dystrophy and DT-818 for myotonic dystrophy type-1.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$DSGN Hedge Fund Activity
We have seen 77 institutional investors add shares of $DSGN stock to their portfolio, and 44 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- POINT72 ASSET MANAGEMENT, L.P. removed 2,649,250 shares (-49.3%) from their portfolio in Q1 2026, for an estimated $28,188,020
- TANG CAPITAL MANAGEMENT LLC removed 1,780,975 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $16,705,545
- RA CAPITAL MANAGEMENT, L.P. added 1,511,592 shares (+103.4%) to their portfolio in Q1 2026, for an estimated $16,083,338
- DRIEHAUS CAPITAL MANAGEMENT LLC added 565,170 shares (+47.9%) to their portfolio in Q1 2026, for an estimated $6,013,408
- MPM BIOIMPACT LLC removed 555,187 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $5,207,654
- LOGOS GLOBAL MANAGEMENT LP removed 550,000 shares (-22.0%) from their portfolio in Q1 2026, for an estimated $5,852,000
- FRAZIER LIFE SCIENCES MANAGEMENT, L.P. removed 521,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $5,543,440
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$DSGN Analyst Ratings
Wall Street analysts have issued reports on $DSGN in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Leerink Partners issued a "Outperform" rating on 12/03/2025
- RBC Capital issued a "Outperform" rating on 11/20/2025
To track analyst ratings and price targets for $DSGN, check out Quiver Quantitative's $DSGN forecast page.
$DSGN Price Targets
Multiple analysts have issued price targets for $DSGN recently. We have seen 5 analysts offer price targets for $DSGN in the last 6 months, with a median target of $15.0.
Here are some recent targets:
- Kostas Biliouris from Oppenheimer set a target price of $21.0 on 05/04/2026
- Faisal Khurshid from Jefferies set a target price of $15.0 on 03/16/2026
- Leonid Timashev from RBC Capital set a target price of $14.0 on 03/10/2026
- Joseph Schwartz from Leerink Partners set a target price of $14.0 on 12/03/2025
Full Release
CARLSBAD, Calif., May 17, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, will announce data from the ongoing Phase 1/2 RESTORE-FA trial evaluating DT-216P2 in patients with Friedreich’s ataxia (FA) on Monday, May 18, 2026. Management will host a conference call and webcast at 8:00 a.m. ET.
A live webcast of the presentation will be available here and in the investors section of the company’s website at www.designtx.com . The webcast will be archived for at least 30 days following the presentation.
About Design Therapeutics
Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC
®
gene targeted chimera small molecules. The company’s GeneTAC
®
molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its clinical-stage GeneTAC
®
programs, DT-216P2, in development for patients with Friedreich ataxia, DT-168, for Fuchs endothelial corneal dystrophy, and DT-818, for myotonic dystrophy type-1, the company is advancing a program in Huntington’s disease. Discovery efforts are underway for multiple genomic medicines. For more information, please visit designtx.com.
Contact:
Renee Leck, THRUST
[email protected]
